Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Quick Take & Core Data: Average body weight reduction: 30.3% at 104 weeks [1] Dose cohort outcome: 45% of patients in the 12 mg group lost 30% or more body weight [1] Diabetic weight loss efficacy: 16.8% reduction over 40 weeks [2] Retatrutide is a triple agonist that binds directly to three metabolic pathways [1, 3]
These changes activate the microbiotabile acidfarnesoid X receptor (FXR) signaling pathway, leading to significant reductions in renal damage
Who shouldnt take GLP-1 medications
Studies included in all three reviews were conducted mainly in middle- and high-income countries, with limited or no representation from regions such as Africa, Central America, and Southeast Asia
Our team is here to provide guidance, answer questions, and encourage you throughout your journey
The retatrutide FDA timeline hinges on Phase 3 readouts
US$ 25.57
US$ 20.56
US$ 25.45
US$ 27.19
US$ 20.52
